by 
Leukemia is a type of cancer that affects the blood and bone marrow cells. It is caused by mutations in the genetic material of hematopoietic stem and progenitor cells in the bone marrow. Leukemia screening helps in early detection of the disease through blood tests and bone marrow biopsies. The global leukemia screening market encompasses various techniques such as flow cytometry, fluorescence in situ hybridization, polymerase chain reaction, and next-generation sequencing that aid in identification of abnormal cells present in blood or bone marrow. Advancements in diagnostic modalities have enabled sensitive detection of genetic abnormalities associated with leukemia.
The global leukemia screening Market is estimated to be valued at US$ 7.28 Bn in 2023 and is expected to exhibit a CAGR of 7.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The development of novel diagnostic techniques is expected to flourish the leukemia screening market over the forecast period. Usage of new biomarker panels and advanced genetic testing methods is enabling early-stage diagnosis of leukemia with high accuracy. For instance, next-generation sequencing allows comprehensive analysis of genetic mutations from a small blood or bone marrow sample. This facilitates detection of minimal residual disease and monitoring of treatment response. Additionally, portable microfluidic devices are being developed for point-of-care leukemia screening. This would significantly improve access to testing in remote areas. Growing research in liquid biopsy tests is also anticipated to transform leukemia management by enabling non-invasive monitoring through blood samples. Widespread adoption of such advanced technologies could boost market growth during the forecast period.
Segment Analysis
The leukemia screening market is segmented based on product type, technology, end user, and region. Based on product type, the market is segmented into service and assay kit. The assay kit segment dominated the market in 2022 owing to increasing usage of assay kits for leukemia diagnosis. Assay kits offer quick and accurate diagnosis of various types of leukemia like acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia.
PEST Analysis
Political: Government initiatives to spread leukemia screening awareness along with funding for research activities influence the market growth. Economic: Rising healthcare expenditure and increasing demand for quick and accurate leukemia diagnosis drive the market growth. Social: Rising incidence of leukemia and increasing awareness regarding early diagnosis fuel the market expansion. Technological: Advancements in molecular diagnostics, flow cytometry, and digital PCR technologies help improve leukemia detection and influence the market positively.
Key Takeaways
The global Leukemia Screening Market is expected to witness high growth during the forecast period of 2023 to 2030.
Regional analysis indicates that North America dominated the market in 2022 owing to presence of major players, developed healthcare system, and increased adoption of advanced molecular diagnostic technologies for leukemia screening.
Key players operating in the leukemia screening market are F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Sysmex Corporation, Bio-Rad Laboratories, Inc., QIAGEN N.V., Beckman Coulter, Inc., Adaptive Biotechnologies Corporation, Invivoscribe, Inc., and ArcherDX, Inc. F. Hoffmann-La Roche Ltd offers high-quality leukemia screening assays like AML Panel, BCR-ABL1 Panel, IGH, IGK, IGL Panel. Thermo Fisher Scientific Inc provides robust flow cytometry solutions and molecular diagnostic platforms for leukemia detection.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
